Browsing Tag

Windtree Therapeutics

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early…

Eli Pacheco Sep 29, 2022 0

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute…

Health

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to…

Eli Pacheco Jun 30, 2022 0

Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.…

Health

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a…

Eli Pacheco Oct 25, 2021 0

WARRINGTON, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage…